Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Tofacitinib taken by mouth helps treat hair loss in children.

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.

Upadacitinib may cause hair loss.

Upadacitinib effectively treated severe hair loss in a child.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

AD198 is more effective than doxorubicin in stopping certain dog cancer cells.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.

Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

EGFR-TKIs can cause unexpected skin, nail, and hair issues.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Hair color loss can indicate the effectiveness of a drug targeting the KIT protein in mice and humans.